Nilotinib

Nilotinib
Clinical data
Trade names	Tasigna, others
Other names	AMN107
AHFS/Drugs.com	Monograph
MedlinePlus	a608002
License data	US DailyMed: Nilotinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	L01EA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	30%
Protein binding	98%
Metabolism	Liver (mostly CYP3A4-mediated)
Elimination half-life	15-17 hours
Excretion	Faeces (93%)
Identifiers
	IUPAC name 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide;
CAS Number	641571-10-0 ;
PubChem CID	644241;
IUPHAR/BPS	5697;
DrugBank	DB04868 ;
ChemSpider	559260 ;
UNII	F41401512X;
KEGG	D08953 ;
ChEBI	CHEBI:52172 ;
ChEMBL	ChEMBL255863 ;
PDB ligand	NIL (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID5042663 ;
ECHA InfoCard	100.166.395
Chemical and physical data
Formula	C28H22F3N7O
Molar mass	529.527 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F;
	InChI InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37) ; Key:HHZIURLSWUIHRB-UHFFFAOYSA-N ;
	(what is this?) (verify)

Nilotinib, sold under the brand name Tasigna among others, is an anti-cancer medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome.^[2]^[6] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.^[2]^[6]^[7] It is taken by mouth.^[2]^[7]

Common side effects may include low platelets, low white blood cells, anemia, rashes, vomiting, diarrhea, and joint pains.^[7] Other serious side effects may include QT prolongation, sudden death, pancreatitis, and liver problems.^[7] It is not safe for use during pregnancy.^[7] Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell.^[2]^[7]

Nilotinib was approved for medical use in the United States in 2007.^[2]^[7] It is on the World Health Organization's List of Essential Medicines.^[8] It is approved as a generic medication.^[9]

^ "Tasigna Summary of Product Characteristics (SmPC)". (emc). October 5, 2023. Archived from the original on March 2, 2024. Retrieved November 13, 2024.
^ ^a ^b ^c ^d ^e ^f "Tasigna- nilotinib capsule". DailyMed. February 8, 2024. Retrieved March 9, 2024.
^ "Danziten- nilotinib tablet". DailyMed. November 1, 2024. Retrieved December 23, 2024.
^ "Tasigna EPAR". European Medicines Agency (EMA). May 22, 2006. Retrieved August 27, 2024.
^ ^a ^b ^c ^d ^e Cite error: The named reference MSR was invoked but never defined (see the help page).
^ ^a ^b "Nilotinib". National Cancer Institute. February 1, 2008. Archived from the original on July 14, 2021. Retrieved November 14, 2019.
^ ^a ^b ^c ^d ^e ^f ^g "Nilotinib Monograph for Professionals". Drugs.com. Archived from the original on July 14, 2021. Retrieved November 14, 2019.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^ "First-Time Generic Drug Approvals 2024". U.S. Food and Drug Administration (FDA). March 8, 2024. Archived from the original on January 26, 2021. Retrieved March 9, 2024.